Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Study finds flaws in risk assessment for OTC statins

Government advisers may consider one-off immunisation for meningitis C at 14 months after a Dutch study found it was far more cost-effective than the UK schedule.

Researchers calculated that a one-off vaccine would provide up to 95 per cent of the protection of the two-, three- and four-month schedule and would be twice as cost-effective.

The three-part UK schedule costs £100,000 more per life year saved, according to the study, published in Vaccine (November).

The Joint Committee on Vaccination and Immunisation is currently reviewing the UK schedule, after concerns that immunity may drop off in older children and suggestions that a booster at 14 months might be required.

Dr Mary Ramsay, consultant epidemiologist at the Health Protection Agency, said babies had been given meningitis C at two, three and four months because of concerns that later vaccination could leave them unprotected.

But she said more recent UK evidence suggested herd immunity was sufficient to protect young children.

Dr Ramsay added: 'The Netherlands, which had the UK evidence when it introduced Men C in 2002, decided to vaccinate only children over 12 months. The UK schedule is under review.'

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say